Catella-Lawson F - Search Results

1

Analysis of the effect of COX-2 specific inhibitors and recommendations for their use in clinical practice.

Lipsky PE, Abramson SB, Breedveld FC, Brook P, Burmester R, Buttgereit F, Cannon GW, Catella-Lawson F, Crofford LJ, Doherty M, Dougados M, DuBois RN, Froelich J, Garcia Rodriguez LA, Gibofsky A, Hernandez-Diaz S, Hochberg MC, Krause A, Liang MH, Machold K, Peloso PM, Raisz LG, Schayes B, Scheiman JM, Simon LS, Smolen J. Lipsky PE, et al. Among authors: catella lawson f. J Rheumatol. 2000 Jun;27(6):1338-40. J Rheumatol. 2000. PMID: 10852251 No abstract available.

2

Cyclooxygenase inhibition and thrombogenicity.

Catella-Lawson F, Crofford LJ. Catella-Lawson F, et al. Am J Med. 2001 Feb 19;110 Suppl 3A:28S-32S. doi: 10.1016/s0002-9343(00)00683-5. Am J Med. 2001. PMID: 11173047 Review.

3

Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases.

Crofford LJ, Oates JC, McCune WJ, Gupta S, Kaplan MJ, Catella-Lawson F, Morrow JD, McDonagh KT, Schmaier AH. Crofford LJ, et al. Among authors: catella lawson f. Arthritis Rheum. 2000 Aug;43(8):1891-6. doi: 10.1002/1529-0131(200008)43:8<1891::AID-ANR28>3.0.CO;2-R. Arthritis Rheum. 2000. PMID: 10943882 Free article.

4

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin.

Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Catella-Lawson F, et al. N Engl J Med. 2001 Dec 20;345(25):1809-17. doi: 10.1056/NEJMoa003199. N Engl J Med. 2001. PMID: 11752357 Free article. Clinical Trial.

5

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.

Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Catella-Lawson F, et al. J Pharmacol Exp Ther. 1999 May;289(2):735-41. J Pharmacol Exp Ther. 1999. PMID: 10215647 Clinical Trial.

6

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.

McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. McAdam BF, et al. Among authors: catella lawson f. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):272-7. doi: 10.1073/pnas.96.1.272. Proc Natl Acad Sci U S A. 1999. PMID: 9874808 Free PMC article.

7

Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects.

Catella-Lawson F. Catella-Lawson F. Neurology. 2001;57(5 Suppl 2):S5-7. doi: 10.1212/wnl.57.suppl_2.s5. Neurology. 2001. PMID: 11552047 Review.

8

Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease.

Catella-Lawson F, Kapoor S, Moretti D, De Marco S, Vigilante GJ, Cucchiara AJ, Ramsey KE, Combe S, Rocca B, Theroux P, FitzGerald GA; AFIRME Investigators. Antagonism of the Fibrinogen Receptor after Myocardial Events. Catella-Lawson F, et al. Am J Cardiol. 2001 Aug 1;88(3):236-42. doi: 10.1016/s0002-9149(01)01632-0. Am J Cardiol. 2001. PMID: 11472700 Clinical Trial.

9

A randomized, placebo-controlled, crossover study of E5510 and aspirin in healthy volunteers.

Reilly MP, Moran N, Meagher E, Delanty N, Cucchiara AE, Lawson JA, Catella-Lawson F. Reilly MP, et al. Among authors: catella lawson f. J Cardiovasc Pharmacol. 1999 Jan;33(1):12-8. doi: 10.1097/00005344-199901000-00003. J Cardiovasc Pharmacol. 1999. PMID: 9890391 Clinical Trial.

10

Direct thrombin inhibitors in cardiovascular disease.

Catella-Lawson F. Catella-Lawson F. Coron Artery Dis. 1997 Feb;8(2):105-11. doi: 10.1097/00019501-199702000-00007. Coron Artery Dis. 1997. PMID: 9211051 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters